Stock listing
TPEx:6785 Alar Pharmaceuticals Inc (昱展新藥) 股價
Follow Alar Pharmaceuticals Inc into a list and get an email when it puts out news.
Share price · TPEX:6785
$59.70 TWD -12.30 (-17.1%)
Close on Nov 20, 2026
- Day range
- $59.70 – $65.20 TWDNov 20, 2026
- Volume
- 198,624 sharesNov 20, 2026
- Market cap
- $3.99B TWDAt the close on Nov 20, 2026 · price × 66.80M shares outstanding
- 52-week range
- $59.70 – $317.00 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.10M TWDMedian day 44,024 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:6785 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $59.70 | -12.30 | -17.1% | $65.20 | $65.20 | $59.70 | 198,624 | |
| $72.00 | -3.90 | -5.1% | $75.00 | $75.00 | $72.00 | 38,853 | |
| $75.90 | -1.20 | -1.6% | $76.00 | $76.60 | $73.80 | 57,465 | |
| $77.10 | -3.60 | -4.5% | $80.30 | $81.60 | $77.10 | 29,797 | |
| $80.70 | -0.20 | -0.2% | $80.10 | $84.00 | $80.00 | 24,232 | |
| $80.90 | +0.80 | +1.0% | $80.10 | $81.00 | $77.70 | 49,137 | |
| $80.10 | +3.60 | +4.7% | $76.60 | $82.70 | $76.60 | 61,336 | |
| $76.50 | 0.00 | 0.0% | $77.00 | $77.00 | $75.10 | 26,129 | |
| $76.50 | +2.70 | +3.7% | $73.80 | $78.50 | $73.80 | 45,077 | |
| $73.80 | -5.10 | -6.5% | $71.10 | $77.00 | $71.10 | 195,238 | |
| $78.90 | -4.00 | -4.8% | $84.00 | $86.00 | $78.90 | 71,756 | |
| $82.90 | +0.90 | +1.1% | $82.40 | $85.50 | $80.20 | 65,943 | |
| $82.00 | -4.50 | -5.2% | $85.00 | $85.30 | $82.00 | 72,794 | |
| $86.50 | +2.50 | +3.0% | $84.10 | $86.50 | $84.10 | 26,851 | |
| $84.00 | -1.00 | -1.2% | $85.00 | $85.00 | $82.00 | 25,645 | |
| $85.00 | -0.80 | -0.9% | $84.20 | $87.50 | $84.00 | 43,592 | |
| $85.80 | +0.30 | +0.4% | $85.60 | $85.80 | $85.00 | 9,585 | |
| $85.50 | -1.40 | -1.6% | $84.50 | $85.50 | $84.00 | 12,435 | |
| $86.90 | 0.00 | 0.0% | $86.90 | $86.90 | $86.90 | 0 | |
| $86.90 | -1.60 | -1.8% | $88.20 | $88.30 | $86.30 | 42,535 | |
| $88.50 | +2.30 | +2.7% | $86.20 | $93.00 | $86.20 | 84,473 | |
| $86.20 | -0.20 | -0.2% | $86.40 | $86.40 | $86.00 | 26,056 | |
| $86.40 | +0.70 | +0.8% | $85.30 | $86.50 | $83.90 | 26,987 | |
| $85.70 | +2.60 | +3.1% | $83.10 | $86.80 | $83.10 | 48,004 | |
| $83.10 | -1.60 | -1.9% | $85.10 | $85.10 | $81.10 | 69,000 | |
| $84.70 | -0.30 | -0.4% | $84.20 | $85.30 | $84.20 | 24,000 | |
| $85.00 | -1.20 | -1.4% | $86.50 | $86.60 | $84.20 | 72,000 | |
| $86.20 | -1.90 | -2.2% | $88.10 | $88.20 | $86.00 | 78,000 | |
| $88.10 | -2.70 | -3.0% | $90.30 | $90.50 | $88.10 | 77,001 | |
| $90.80 | -2.30 | -2.5% | $92.10 | $92.20 | $90.10 | 136,000 | |
| $93.10 | -1.30 | -1.4% | $94.10 | $94.10 | $92.80 | 44,026 | |
| $94.40 | -0.30 | -0.3% | $94.70 | $94.80 | $94.00 | 43,000 | |
| $94.70 | -0.60 | -0.6% | $95.10 | $95.40 | $94.20 | 33,012 | |
| $95.30 | +0.20 | +0.2% | $95.30 | $96.00 | $95.00 | 31,130 | |
| $95.10 | -1.10 | -1.1% | $96.30 | $97.70 | $94.80 | 66,030 | |
| $96.20 | -2.60 | -2.6% | $97.30 | $97.40 | $96.20 | 29,000 | |
| $98.80 | -0.10 | -0.1% | $100.00 | $100.00 | $97.00 | 44,021 | |
| $98.90 | +2.70 | +2.8% | $96.60 | $99.20 | $96.20 | 21,000 | |
| $96.20 | -3.30 | -3.3% | $101.00 | $101.00 | $96.20 | 82,000 | |
| $99.50 | +0.50 | +0.5% | $99.80 | $100.00 | $98.00 | 46,000 | |
| $99.00 | -5.00 | -4.8% | $104.50 | $108.00 | $99.00 | 226,050 | |
| $104.00 | +9.40 | +9.9% | $95.00 | $104.00 | $94.10 | 167,001 | |
| $94.60 | +0.60 | +0.6% | $95.00 | $95.40 | $94.20 | 16,000 | |
| $94.00 | +0.70 | +0.8% | $91.30 | $94.50 | $91.30 | 27,000 | |
| $93.30 | -0.70 | -0.7% | $95.40 | $95.60 | $93.20 | 15,040 | |
| $94.00 | -1.60 | -1.7% | $96.70 | $96.70 | $93.10 | 31,000 | |
| $95.60 | +1.00 | +1.1% | $97.30 | $97.40 | $94.00 | 37,000 | |
| $94.60 | +1.60 | +1.7% | $94.00 | $96.00 | $92.40 | 55,000 | |
| $93.00 | -1.00 | -1.1% | $93.30 | $93.30 | $92.00 | 52,000 | |
| $94.00 | +2.10 | +2.3% | $92.00 | $94.10 | $91.10 | 44,020 | |
| $91.90 | +1.20 | +1.3% | $92.20 | $92.30 | $90.70 | 27,010 | |
| $90.70 | -0.50 | -0.5% | $91.20 | $92.70 | $90.60 | 35,002 | |
| $91.20 | -1.00 | -1.1% | $92.10 | $93.00 | $90.70 | 45,000 | |
| $92.20 | -2.50 | -2.6% | $94.10 | $94.60 | $92.20 | 88,010 | |
| $94.70 | -0.60 | -0.6% | $94.10 | $95.30 | $93.00 | 63,000 | |
| $95.30 | -2.80 | -2.9% | $97.20 | $97.20 | $95.20 | 43,000 | |
| $98.10 | -1.20 | -1.2% | $97.30 | $98.40 | $97.00 | 30,000 | |
| $99.30 | +3.60 | +3.8% | $95.80 | $99.80 | $95.70 | 50,000 | |
| $95.70 | -3.10 | -3.1% | $96.70 | $97.30 | $95.20 | 71,023 | |
| $98.80 | -1.20 | -1.2% | $98.20 | $98.80 | $97.00 | 18,000 | |
| $100.00 | +0.80 | +0.8% | $101.00 | $105.50 | $98.50 | 178,000 | |
| $99.20 | +0.90 | +0.9% | $98.10 | $100.50 | $97.00 | 71,000 |
- Ticker
- TPEx:6785
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
What changed lately
Latest news
Alar Pharmaceuticals Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Apr 6, 2026 · oldest 2026
Valuation
EV/sales 568× against a median of 2.1×: the highest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.70B TWD
- P/E
- Loss
- EV/sales
- 568×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.66M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.3× | n/a | n/a | −146.4% | n/a | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| STCube, Inc. · KRX:052020 | US$117.7M | US$71.99M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Median of the others | US$122.0M | US$70.61M | 18.4× | 2.1× | 12.3× | 2.2× | −222.2% | 0.1× | 1.22 |
Team and board
Officers
| Officer | Role |
|---|---|
| Yung-Shun Wen | CEO |
| Vivian Kang | Director of Finance |
Board
| Director | Role |
|---|---|
| Charles Lin | Chairman |
| Chen-Yu Fang | Director |
| Shoei-Sheng Lee | Independent Director |
| Shu-Chin Liang | Independent Director |
| Su Fnag Yang | Independent Director |
| Yung-Shun Wen | CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | Nov 6, 2024 · After close | +0.3% |
| Q2 2024 | Aug 7, 2024 · After close | +0.3% |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.75M | 5.82M | 469.3M | 800.0K | 0 | 600.0K |
| Cost of revenue | 613.0K | 2.03M | 0 | |||
| Gross profit | 2.14M | 3.79M | 469.3M | 800.0K | 600.0K | |
| Research and development | 156.5M | 57.3M | 56.7M | 34.2M | 81.9M | 160.3M |
| Selling, general and administrative | 13.4M | 14.4M | 27.0M | 13.1M | 11.4M | 11.0M |
| Operating income | -167.8M | -67.9M | 391.2M | -32.5M | -64.2M | -142.8M |
| Depreciation and amortization | 4.87M | 3.88M | 3.35M | 3.21M | 3.36M | 2.84M |
| EBITDA | -162.9M | -64.1M | 394.5M | -29.3M | -60.9M | -139.9M |
| Interest expense | 81.0K | 27.0K | 63.0K | 22.0K | 21.0K | 33.0K |
| Income before tax | -79.0M | 37.0M | 391.1M | -32.5M | -64.2M | -142.8M |
| Income tax | 8.49M | -12.7M | ||||
| Net income | -79.7M | 18.2M | 382.6M | -19.9M | -64.2M | -142.8M |
| Earnings per share, basic | -1.19 | 0.27 | 6.71 | -0.35 | -1.13 | -2.86 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.79B | 1.41B | 739.5M | 455.4M | 519.1M | 561.0M | |
| Short-term investments | 502.9M | 1.03B | 156.5M | 30.9M | 22.7M | 128.5M | |
| Receivables | 0 | 840.0K | 0 | ||||
| Current assets | 2.35B | 2.44B | 903.0M | 497.6M | 528.7M | 591.4M | 128.5M |
| Total assets | 2.49B | 2.56B | 973.2M | 522.6M | 539.9M | 604.0M | |
| Accounts payable | 145.0K | ||||||
| Current liabilities | 74.5M | 55.1M | 74.8M | 5.37M | 4.46M | 4.13M | 145.0K |
| Total debt | 1.41M | 2.69M | 949.0K | 1.52M | |||
| Total liabilities | 84.3M | 64.3M | 76.1M | 8.10M | 5.54M | 5.37M | 145.0K |
| Shareholders' equity | 2.40B | 2.49B | 897.1M | 514.5M | 534.4M | 598.6M | |
| Shares outstanding | 66.8M | 66.8M | 57.1M | 57.0M | 57.0M | 49.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -171.0M | -75.3M | 403.6M | -32.9M | -63.5M | -141.9M |
| Capital spending | -2.87M | -1.23M | -6.34M | -1.14M | -1.58M | -385.0K |
| Free cash flow | -173.9M | -76.5M | 397.2M | -34.1M | -65.0M | -142.3M |
| Cash from financing | -1.28M | -929.0K | -932.0K | 549.1M | ||
| Dividends paid | -16.7M | -100.2M | ||||
| Change in cash | 387.7M | 666.4M | 284.1M | -63.7M | -41.9M | 511.5M |
Cap table
Built by 6ix from Alar Pharmaceuticals Inc’s releases
- Common shares
- 66,800,000
- Fully diluted
- 66,800,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 66,800,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 66,800,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charles Lin | Chairman · Since at least Apr 6, 2026 |
| Chen-Yu Fang | Director · Since at least Nov 5, 2026 |
| Shoei-Sheng Lee | Independent Director · Since at least Nov 5, 2026 |
| Shu-Chin Liang | Independent Director · Since at least Nov 5, 2026 |
| Su Fnag Yang | Independent Director · Since at least Nov 5, 2026 |
| Vivian Kang | Director of Finance · Since at least Nov 5, 2026 |
| Yung-Shun Wen | CEO · Since at least Apr 6, 2026 |
Log in to ask 6ix AI your own questions about Alar Pharmaceuticals Inc.